Brandan K. Penaluna, MD, MBA

Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota.

  • 1Article
  • 2.4KReads1
  • 2026Active
  • 12Collaborators
  • 2Citations2

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

About

Brandan K. Penaluna, MD, MBA is affiliated with Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota. Brandan K. Penaluna has contributed 1 peer-reviewed article published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders in 2026. Their work focuses on Depression (MDD).

Publications

JCP
Next-Step Treatment Options for Treatment-Resistant Depression
Consensus Statement

Next-Step Treatment Options for Treatment-Resistant Depression

January 21, 2026

Strong consensus emerged for augmentation with second-generation antipsychotics, TMS, and ketamine/esketamine in the base vignette. Preferences shifted to include non-augmentative antidepressants and ECT based on patient characteristics.
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Ketamine and Psychedelics

Listen to the Podcast
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe